登录 | 注册    关注公众号  
搜索

GUCY2C信息

英文名称:Heat-stable enterotoxin receptor
中文名称:热稳定肠毒素受体
靶点别称:GUC2C,Intestinal guanylate cyclase,hSTAR,EC:4.6.1.2,EC 4.6.1,GC-C,GUCY2C,Guanylate Cyclase 2C,STA Receptor,Guanylyl Cyclase C,Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor),Heat-Stable Enterotoxin Receptor,STAR,Heat Stable Enterotoxin Receptor,EC 4.6.1.2,DIAR6,MECIL,MUCIL
上市药物数量:1
临床药物数量:3
最高研发阶段:批准上市

GUCY2C产品列表

 
评论(3)
GUC-C52H6|Cynomolgus GUCY2C / Guanylyl cyclase C Protein, His Tag (MALS verified)
  1. 187XXXXXXX1
  2. 4人赞
  3. 该抗原经过ELISA实验验证后,与其他供应商的商品相比,与抗体结合的活性较好,适用于后期的免疫学相关实验
  4. >
  5. 2021-10-26
GUC-H52H5|Human GUCY2C / Guanylyl cyclase C Protein, His Tag (MALS verified)
  1. 187XXXXXXX1
  2. 2人赞
  3. 该抗原经过ELISA实验验证后,与其他供应商的商品相比,与抗体结合的活性较好,适用于后期的免疫学相关实验
  4. >
  5. 2021-10-26
GUC-C5255|Cynomolgus GUCY2C / Guanylyl cyclase C Protein, Fc Tag
  1. 187XXXXXXX1
  2. 0人赞
  3. 该抗原经过ELISA实验验证后,与其他供应商的商品相比,与抗体结合的活性较好,适用于后期的动物免疫和免疫学相关实验
  4. 2021-10-26
 

GUCY2C 分子别名

GUCY2C,GUC2C,STAR,STA receptor,hSTAR,GC-C

GUCY2C 分子背景

GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP. Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer.

GUCY2C 前沿进展

GUCY2C上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Plecanatide SP-304; GCRA 批准上市 Synergy Pharmaceuticals Trulance United States 便秘, 慢性特发性便秘 Salix Pharmaceuticals 2017-01-19 便秘, 肠易激综合征, 慢性特发性便秘 详情

GUCY2C临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
GCC19CART GCC19CART 临床一期 上海斯丹赛生物技术有限公司 直肠癌 详情
Dolcanatide SP-333; WU-977T914K 临床二期 Synergy Pharmaceuticals 便秘 详情
PF-07062119 PF-07062119 临床一期 辉瑞制药有限公司 胃癌, 腺癌, 胃肠道癌症, 大肠肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定